Thursday, 17 Oct 2019

You are here

Joint Surgery Rates Remain High in Psoriatic Arthritis

The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.

During the years 1996-2000, the incidence rate of joint surgery was 18.2 per 1,000 person-years among PsA patients compared with 7.2 per 1,000 in the general population, according to Jørgen Guldberg-Møller, MD, of Copenhagen University Hospital in Frederiksberg, Denmark, and colleagues.

This rate remained twice that of the general population by the years 2009-2012, at 21.1 per 1,000 person-years versus 10.7 per 1,000 -- thus increasing in both groups -- despite the availability of effective disease-modifying biologic treatments in PsA, the team reported in Annals of the Rheumatic Diseases.

To shed further light on the question, Guldberg-Møller and colleagues analyzed data from the Danish National Patient Registry, identifying 11,960 patients diagnosed with PsA from 1996 to 2017. (Those enrolled from 2013-2017 were not included in the time trend analysis because they had not been followed for a full 5 years.)

Patients were matched with 109,296 controls drawn from the general population in the national civil registration system. Participants' mean age was 50, and 57% were women.

They found that the incidence rate ratio for first joint surgery among patients with PsA was twice that of the general population for all included time periods:

  • 1996-2000: IRR 2.4 (95% CI 2-2.9)
  • 2001-2004: IRR 2.3 (95% CI 1.9-2.7)
  • 2005-2008: IRR 2 (95% CI 1.7-2.3)
  • 2009-2012: IRR 2 (95% CI 1.7-2.2)

The researchers then compared the incidence rates of joint-sacrificing surgery, defined as arthroplasty and arthrodesis, with non-joint sacrificing surgery, such as procedures involving soft tissue, joint surfaces, or synovium. For joint-sacrificing surgery, the overall rates from 1996-2012 were 10.7 per 1,000 person-years among PsA patients vs 3.7 per 1,000 among controls, and for non-joint sacrificing surgery, the rates were 13 and 7 per 1,000, respectively.

They calculated the cumulative incidence proportions of any joint surgery through 2017. Among PsA patients, these were 1.7% (95% CI 1.4%-2.0%) after 5 years, 10.4% (95% CI 9.6%-11.2%) after 10 years, and 28.9% (95% CI 27.2%-30.6%) after 15 years. Among the general population, the corresponding numbers were 0.5% (95% CI 0.5%-0.6%), 4.6% (95% CI 4.5%-4.8%), and 14.6% (95% CI 14.2%-15.1%), respectively.

Further analysis with age stratification revealed that the risk of joint-related surgery after 15 years of follow-up was higher for PsA patients in all age groups, and that the rate for PsA patients ages 18 to 40 was higher, at 22.4% (95% CI 19.3%-25.6%), than for controls ages ≥60, which was 19.9% (95% CI 18.7%-20.9%).

Moreover, after only 5 years of follow-up, the cumulative incidence of joint-sacrificing surgery was 1.2% (95% CI 0.9%-1.6%) in PsA patients ages 40-60, compared with 0.9% (95% CI 0.7%-1.0%) of controls ages 60 and older.

Overall, the cumulative risk of surgery at 15 years post-diagnosis was 29% among PsA patients in this study, the group found.

The high rate of joint surgery remains "a puzzle," and "an important unmet need," they concluded.

"Future studies will be needed to identify the impact of biological DMARD treatment on the need for surgery using individual-level based information," the authors concluded.

A study limitation, the researchers noted, was the possibility of disease misclassification, which is common to all registry-based studies. And, because of the study's observational design, the authors indicate that it is not clear whether their results reflect changes in referral patterns, or a shift in diagnosis focus.

Source Reference: Annals of the Rheumatic Diseases 2019; DOI: 10.1136/annrheumdis-2019-215313

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Comorbidity Worsens Axial Spondyloarthritis

Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.

One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery

Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.

The Danish National Patient Registry was used in this cohort study of incident PsA patients and their future risk of joint surgery compared to a general population cohort (GPC) between 1995-2012).

FUTURE 5 - Secukinumab and Less Radiographic Progression in Psoriatic Arthritis

The FUTURE 5 trial studied the effect of secukinumab (SEC) on radiographic progression through 52 weeks in patients with active psoriatic arthritis (PsA) and found that SEC was clinically and radiographically superior to placebo (PBO). Patients received s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at week 4. The majority (87%) of patients enrolled at baseline remained in the study for 52 weeks.

Ixekizumab vs. Adalimumab in Psoriatic Arthritis

The Annals of Rheumatic Disease reports a psoriatic arthritis study where in ixekizumab was non-inferior to adalimumab for achievement of ACR50 responses but was superior to adalimumab for achievement of PASI100 by week 24.

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.